Clinical Trials Logo

Pertussis clinical trials

View clinical trials related to Pertussis.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06114160 Not yet recruiting - Pertussis Clinical Trials

Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy

Coqueluche-Vac
Start date: December 1, 2023
Phase:
Study type: Observational

In France, it has been recommended since 2022 that pregnant women be vaccinated against pertussis from 20 to 36 weeks' gestation. This vaccination schedule is inspired by the Anglo-Saxon model and studies showing the effectiveness of this practice. The aim of this vaccine is to protect the newborn by transferring antibodies from the fetus to the placenta, because Pertussis is a particularly serious disease in newborns.

NCT ID: NCT05952596 Not yet recruiting - Hepatitis B Clinical Trials

A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults

Start date: July 17, 2023
Phase: Phase 1
Study type: Interventional

This is a single-center, randomized, active-controlled, parallel-design, double-blind, phase I study to evaluate the safety and immunogenicity of a single dose of APV006 in healthy adults.

NCT ID: NCT05856396 Not yet recruiting - Pertussis Clinical Trials

Maternal Determinants of Infant Immunity to Pertussis

MADI-02
Start date: June 1, 2023
Phase: Phase 4
Study type: Interventional

The overall objective of the project is to identify the determinants of antibody-mediated immunity in infants born to mothers immunized during pregnancy. Using maternal pertussis immunization as a model, the project will identify key predictors and potential determinants of vaccine responses in pregnant women, of the transfer of maternal antibodies to the newborn and of vaccine responses in infants. A systems biology approach will be used to delineate pre-vaccination and post-vaccination cellular and molecular correlates of the immune response to pertussis immunization in peripheral blood and in breastmilk.

NCT ID: NCT05457946 Not yet recruiting - Hepatitis B Clinical Trials

Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series

Start date: April 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate immunogenicity and safety of different doses of candidate hexavalent vaccine in comparison to co-administration of Pentavalent vaccine and Poliomyelitis Vaccine (Inactivated) in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants and thereby to select the optimal dose of candidate vaccine(Stage 1) and to demonstrate lot-to-lot consistency of three lots of LBVD (Stage 2)

NCT ID: NCT04694963 Not yet recruiting - Pertussis Clinical Trials

A Multi-center Study to Determine the Prevalence and Influence of Pertussis on Subacute Cough in Shenzhen

Start date: January 1, 2021
Phase:
Study type: Observational

A prospective, multi-center, observational clinical trail. Aim to evaluate the real incidence of COPD pertussis and the impact of pertussis on subaute cough.

NCT ID: NCT04694430 Not yet recruiting - COPD Exacerbation Clinical Trials

A Multi-center Study to Determine the Prevalence and Influence of Pertussis on COPD Exacerbation in Shenzhen

Start date: January 1, 2021
Phase:
Study type: Observational

A prospective, multi-center, observational clinical trail. Aim to evaluate the real incidence of chronic obstructive pulmonary disease (COPD) pertussis and the impact of pertussis on COPD exacerbation.

NCT ID: NCT04073459 Not yet recruiting - Hepatitis B Clinical Trials

Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants

Start date: November 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate immunogenicity and safety of three different doses of candidate hexvalent vaccine in comparison to co-administration of EupentaTM Inj. and Imovax® Polio in separate injections at four weeks after completion of three-dose primary series at 6-10-14 weeks of age when administered to healthy infants and thereby to select the optimal dose of candidate vaccine

NCT ID: NCT04056728 Not yet recruiting - Hepatitis B Clinical Trials

A Phase IV Study to Assess the Safety of EupentaTM Inj

Start date: September 23, 2019
Phase: Phase 4
Study type: Interventional

A prospective, open-label, interventional phase IV study to assess the safety of EupentaTM Inj.{fully liquid pentavalent vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [recombinant-deoxyribonucleic acid])-Haemophilus influenzae type b conjugate vaccine}

NCT ID: NCT03341195 Not yet recruiting - Tuberculosis Clinical Trials

Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan

Start date: January 2018
Phase: N/A
Study type: Interventional

Routine childhood immunization (RCI) in Pakistan is well below the recommended coverage of 90% with rates as low as 16% in certain regions (Pakistan DHS 2012-3). This has led to continued polio transmission, large measles outbreaks and thousands of deaths from vaccine-preventable diseases (Kazi.Bull WHO 2016). Mobile phone communication is widespread in developing countries and has proven a potential method of directly connecting pregnant women and mothers to health services (Kharbanda. Expert Review of Vaccine 2014). The investigators propose conducting a mixed methods proof of concept cluster randomized trial (CRT) to assess the effectiveness of different types of SMS messaging and automated calls to improve RCI and understand the perceptions and barriers that may affect SMS and automated call-based interventions at participants levels. the investigators will conduct the study at urban and rural sites in Pakistan. The investigators will examine an important public health question - do low cost, automated SMS, and automated messages improve RCI coverage in resource-constrained settings? Further, investigators will compare the effectiveness of reminder, educational and interactive text messages for improving RCI and will generate socio-cultural data regarding the impact of participants health beliefs that will be important for setting up the appropriate interventions in other LMICs.

NCT ID: NCT02257645 Not yet recruiting - Hepatitis B Clinical Trials

Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Weeks

Start date: March 2015
Phase: N/A
Study type: Observational

A multicenter, observational study to evaluate the safety of Euforvac-Hib vaccine for active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenza type B in infants.